Montelukast Sodium Market Report 2026

The montelukast sodium market size has grown strongly in recent years. It will grow from $4.2 billion in 2025 to $4.59 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to longstanding clinical use of montelukast in asthma control, increasing prevalence of allergic respiratory diseases, established safety profile in long-term therapy, widespread physician adoption for maintenance treatment, availability of cost-effective generic versions.

The montelukast sodium market size is expected to see strong growth in the next few years. It will grow to $6.33 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to rising global burden of asthma and allergic rhinitis, growing pediatric asthma diagnosis rates, increased awareness of non-steroidal asthma therapies, expanding access to respiratory medicines in emerging markets, continued demand for oral maintenance drugs. Major trends in the forecast period include rising demand for leukotriene receptor antagonists in asthma management, growing use of montelukast in allergic rhinitis treatment, expansion of generic montelukast sodium formulations, preference for oral solid dosage forms in chronic respiratory therapy, increased prescriptions for pediatric and adult asthma patients.

The rising prevalence of asthma is expected to drive the growth of the montelukast sodium market in the coming years. Asthma is a long term respiratory condition characterized by inflammation and narrowing of the airways, leading to recurring symptoms such as wheezing, shortness of breath, chest tightness, and coughing. The incidence of asthma is increasing due to factors including environmental pollution, exposure to allergens, genetic susceptibility, urbanization, lifestyle changes, and respiratory infections. Montelukast sodium is used in asthma management as a leukotriene receptor antagonist that helps prevent and control symptoms by blocking leukotrienes, which play a key role in airway inflammation and bronchoconstriction. For example, in October 2024, according to the National Asthma Council, an Australia based non profit organization, Australia recorded 474 asthma related deaths in 2023, including 325 females and 149 males. This figure was nearly the same as the 473 asthma related deaths reported in 2022, indicating a consistent pattern in asthma mortality. Therefore, the increasing prevalence of asthma is contributing to the growth of the montelukast sodium market.

Major companies operating in the montelukast sodium market are focusing on the development of innovative solutions such as combination therapies to offer broader relief from allergy and asthma symptoms and to improve patient adherence. Combination therapies involve the use of two or more medications together in a single treatment regimen to target multiple disease pathways and achieve better therapeutic outcomes. For instance, in October 2025, Cadila Pharmaceuticals Ltd., an India based pharmaceutical company, introduced Dlorfast M tablets, a fixed dose combination containing desloratadine 5 mg and montelukast 10 mg for the treatment of allergic rhinitis and urticaria. This formulation delivers comprehensive symptom control by addressing both histamine and leukotriene pathways in a convenient once daily oral dose, aiming to enhance patient compliance and provide sustained relief with good tolerability.

In April 2024, Apotex Inc., a Canada based pharmaceutical company, acquired Searchlight Pharma Inc. for an undisclosed amount. Through this acquisition, Apotex seeks to expand its presence in the branded and specialty pharmaceuticals segment by incorporating Searchlight’s portfolio of innovative and specialty focused products. Searchlight Pharma Inc. is a Canada based specialty branded pharmaceutical company.

Major companies operating in the montelukast sodium market are Pfizer Inc., Merck & Co. Inc., Sanofi Aventis SA, Teva Pharmaceuticals USA Inc., Hetero Labs Ltd., Sun Pharma Industries Ltd., Aurobindo Pharma Limited, Cipla Inc., Intas Pharmaceuticals Ltd., Seqens Group, Sanyo Chemical Industries Ltd., Morepen Laboratories, Neuland Laboratories Ltd., Medopharm Private Ltd., BEC Chemicals Pvt. Ltd, Delmar Chemicals Inc., Kimia Biosciences Ltd., Ortin Laboratories Ltd., MSN Laboratories Pvt Ltd., Vamsi Labs Ltd., LGM Pharma LLC, HRV Global Life Sciences, Sigmak Lifesciences, Akums Lifesciences Ltd., Anwita Drugs & Chemicals Pvt Ltd.

North America was the largest region in the montelukast sodium market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the montelukast sodium market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the montelukast sodium market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the montelukast sodium market by increasing costs for imported active pharmaceutical ingredients, intermediates, and formulation excipients. These impacts have been most evident in regions reliant on cross-border api sourcing, particularly North America and Europe importing from Asia. Higher production costs have affected pricing strategies for generic manufacturers. However, tariffs have also encouraged local api manufacturing and regional formulation capabilities, strengthening domestic supply chains.

The montelukast sodium market research report is one of a series of new reports that provides montelukast sodium market statistics, including montelukast sodium industry global market size, regional shares, competitors with a montelukast sodium market share, detailed montelukast sodium market segments, market trends and opportunities, and any further data you may need to thrive in the montelukast sodium industry. This montelukast sodium market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Montelukast sodium is a leukotriene receptor antagonist that works by blocking the effects of leukotrienes, which are responsible for triggering asthma symptoms and allergic reactions. It is used to prevent and manage asthma symptoms and to treat seasonal and perennial allergic rhinitis. Montelukast is generally administered orally, most commonly in tablet form.

The main product types of montelukast sodium include crystal-like, formless, or amorphous forms. Crystal-like forms refer to solid substances with a regular and repeating three-dimensional molecular structure. The available dosage forms include tablets and oral solutions. These formulations are used for various applications such as bronchospasm, allergic coryza, asthma, urticaria, and others.

The montelukast sodium market consists of sales of monteluksast oral granules, chewable tablets, pill organizers, dosing spoons and syringes, and tablet packaging material. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.